STUDY BASICS
Are you an HIV-negative man who is comfortable discussing your sexual history with researchers? If so, you may be able to participate in a research study to compare the safety and acceptability of a rectal douche containing tenofovir to a pill that prevents HIV. Participation involves about 8 visits over approximately 19 weeks. Compensation provided.
STUDY PURPOSE
This study will test the safety and acceptability of a rectal douche that contains an anti-HIV drug called tenofovir.
COULD THIS STUDY BE RIGHT FOR YOU?
- Males ages 18 and up
- HIV-negative
- History of consensual receptive anal intercourse at least five times and at least once in the prior 3 months
- Have used an enema or douche in past year
WHAT PARTICIPANTS CAN EXPECT
If you are eligible to participate in the study you will come to the clinic for scheduled visits about 8 times over approximately 19 weeks. Each study visit may last about 1 – 2 ½ hours for the main study. You may have to come for more visits if you have a lab or health issue. We may contact you after the study ends (for example, to tell you about the study results).
IRB: SSU00256033
- Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) - HPTN 106, A Phase 2 Crossover Study of On-Demand PrEP Formulations Comparing Rectal and Oral Tenofovir-Based PrEP Evaluating Extended Safety, Acceptability, and Pharmacokinetics/Pharmacodynamics (Pro00077640)MEET THE RESEARCHER
Ken Ho
Ken S. Ho, MD, MPH, is Medical Director at Pitt Men’s Study at the University of Pittsburgh. Dr. Ho’s primary research focuses on biomedical strategies for HIV prevention.